MICA: Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition - a phase IIa study

Lead Research Organisation: Newcastle University
Department Name: Translational and Clinical Res Institute

Abstract

Context
Rheumatoid arthritis (RA) is a condition in which the joints become inflamed and painful. It affects about 1 in every 100 adults in the UK. It is thought to be caused by the patient's immune system mistakenly attacking their joints. The resulting inflammation is not only painful but reduces joint movement and eventually causes joint damage and deformity. RA can also affect other organs such as the lungs, and patients with RA also have a higher than average risk of developing heart attacks and strokes. They are also more susceptible to infections. Many patients lose their jobs soon after the diagnosis is made.

Aims and objectives
Most drugs currently used to treat RA neutralise the inflammation (anti-inflammatory drugs, steroids) or the cells of the immune system and their products (biological therapies or 'magic bullets'). Over the past 20 years the outcome for RA patients has improved, partly because of earlier and more 'aggressive' treatment (more drugs, higher doses) and partly because of new therapies that have been developed (particularly the 'magic bullets'). However, many patients don't respond completely to these treatments and some don't respond at all. We believe that there is another type of cell responsible for the symptoms in these patients. The fibroblast is a cell that is present in healthy joints, where it is important for normal joint function. However, fibroblasts divide inappropriately and become more numerous and 'aggressive' in RA joints. They damage the joint by producing chemicals that eat into cartilage and bone, and also produce inflammatory chemicals themselves.

Thus, a useful cell in health becomes one that causes inflammation and joint damage in RA. As far as we know none of the current treatments affect the behaviour of fibroblasts. Our plan is test a drug in RA patients that we think will do so. The drug interferes with the machinery that is necessary for cells to divide. Fibroblasts in the RA joint seem particularly sensitive to this drug, which we therefore believe can correct their abnormal behaviour. The drug has already been tested in patients with certain types of cancer (in which cells also divide inappropriately) and seems safe enough to test in RA. We aim to show that the treatment is safe in RA, and that it could provide a useful treatment for RA patients.

The research is divided into two parts. In the first part we will test the safety of different doses of the drug over 4 weeks of treatment. We will identify a dose that is both safe and appropriate to test in more patients for a longer period of time. In the second part we will give this dose to 12 RA patients for 12 weeks. At the same time 6 patients will receive an identical 'placebo' treatment. This is important to ensure that any effects we see are due to the drug and not other factors (more visits to the hospital, more interaction with doctors and nurses). As well as checking the patients' symptoms, we will also perform scans of their joints at the start and end of the treatment. We will also take small samples of joint tissue (biopsies). These scans and biopsies will help us to decide whether the treatment is working and how it is working. This is important to help us to decide whether the trial has been a 'success' and whether to perform further trials later on.

Potential applications and benefit
In this trial we will treat patients who have had RA for at least a year and who are already taking treatment but not responding well enough. This will test our idea that we can improve their symptoms by altering the behaviour of the fibroblasts. If this research is successful then we will need to test the treatment in RA patients taking different treatments, at different stages of their illness. Because this treatment works in such a different way to existing drugs, we believe it could be useful for many different types of RA patient. Later on, if safe and effective, it may also be useful in other diseases.

Technical Summary

This project aims to repurpose a small molecule anti-cancer drug as an anti-fibroblast drug for RA. The past 20 years have seen major advances in RA therapy; more aggressive use of conventional drugs, and biological targeted therapies have each made a significant impact. However, disease remission remains uncommon and around 20% of patients remain refractory to all therapies. This represents a significant unmet need and suggests key aspects of RA pathogenesis remain untargetted.
In health, a delicate nutritive synovial membrane (SM) lines joint cavities. This comprises a few macrophages and fibroblasts in a loose connective tissue stroma. In RA the SM is the focus of autoimmune attack but, in addition to inflammatory cell infiltration, resident synovial fibroblasts (SF) become hyperplastic, forming a vascularised, inflammatory, quasi-malignant pannus which invades articular cartilage and bone. The resultant joint damage underlies the disability and reduced quality of life that characterise RA.
Cell proliferation relies on the coordinated activation of specific regulatory proteins: orderly progression through the cell cycle is tightly controlled by the formation and activation of complexes comprising cyclin proteins and cyclin-dependent kinases (CDK). These complexes are in turn regulated by endogenous CDK inhibitors (CDKI). The concept of inhibiting CDKs to correct uncontrolled cell proliferation has led to the evaluation of small molecule CDKI in cancer.
RA SF have reduced endogenous CDKI levels, and correction of the deficit normalises their dysregulated phenotype. Indeed, small molecule CDKI ameliorate synovitis in pre-clinical arthritis models. In partnership with the SME Cyclacel, we propose a phase IIa repurposing study of a CDKI in patients with refractory RA. Stage 1 will focus on safety and tolerability, to determine an appropriate dose to progress to stage 2, where we will seek evidence of potential therapeutic activity alongside PK and PD biomarkers.

Planned Impact

Our research aims to deliver a new drug and a novel therapeutic approach, therefore potential beneficiaries include patients, the NHS, the life sciences industry, UK plc, Arthritis Research UK and other funders, the project team and other academic researchers.
Patients with RA will derive the most immediate impact from our research, which could provide a novel therapy with a unique mechanism of action. This could result in better disease control, improved quality of life and reduced long-term complications, either as a monotherapy or in combination with existing drugs. Success will also stimulate research into related compounds from the same class as well as alternative anti-fibroblast drugs and targets (eg pro-apoptosis, epigenetic modifiers, anti-proliferative). It will also stimulate research into potential applications in other fibrotic diseases - all with potential downstream beneficial impact on patients. Via our Engagement programmes this work will have a wider impact on patients by reinforcing the benefits of participating in early phase experimental medicine research.
For similar reasons success will provide a boost to the UK life sciences industry. Clearly our Partner would benefit greatly but so too will other SMEs, biotechs, and pharma with alternative drugs from the same class, as well as drugs with the potential to target the fibroblast in a distinct manner. Our research would provide a novel target and a novel paradigm for the treatment of RA and would also trigger a re-analysis of exisiting compounds that may have therapeutic potential in RA or, indeed, other fibrotic diseases. RA remains a disease with a high unmet need and provides potentially high investment returns. Some of the other potential disease targets could become 'orphan' indications, with a more commercially favourable path to the clinic.
Downstream success will lead to a workforce with an improved skill set, including UK/EU contract manufacturing capabilities, and specialist PK testing. Ultimately successful development of a novel drug for RA will deliver substantial revenue to the UK and catalyse additional activity in the healthcare sector. It will also impact on HM Government by reinforcing the benefits of their investment in the life sciences industry.
We are using UK based companies for sub-contracted work. This will have a positive impact on income generated and jobs protected within home countries.
Because our research involves an orally available drug, it would likely be cheaper than the biologic drugs. If it substituted for them in the treatment pathway, or improved their efficacy as hypothesised, this would ultimately result in direct or indirect cost-savings to the NHS.
In addition to the MRC, Arthritis Research UK, NIHR, the Wellcome Trust, the partner Universities and NHS Trusts will benefit from our research, because they are providing some of the infrastructure and staff needed to perform this research. They would therefore be in a position to share in the success. The development of a new drug for RA would likely lead to an increase in charitable donations to relevant charities.
Success will impact on the project team both directly, via the experience and educational opportunities of performing a successful phase II experimental medicine study; and also indirectly from the emotional and psychological benefits of involvement with a study that could potentially benefit thousands of patients.
Lastly, other academic researchers will clearly derive impact from this research, which will provide them directly with new ideas and opportunities, and indirectly by increasing collaborative opportunities with one another and with the life sciences sector.
 
Description A: Arthritis Research UK Disease Subcommittee Meeting, Chesterfield, 2018
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
URL https://www.versusarthritis.org/research/research-funding-and-policy/our-charitable-subcommittees/
 
Description A: NIHR ARUK Musculoskeletal Experimental Medicine Conference 2018, Nottingham 2018
Geographic Reach National 
Policy Influence Type Participation in a national consultation
URL https://www.arthritisresearchuk.org/research/news-for-researchers/2018/july/maximising-msk-experimen...
 
Description Arthritis Research UK Strategic Workshop - Stacking the Odds Towards a Cure - Versus Arthritis London 2018
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Associate Medical Director for Research, Newcastle upon Tyne Hospitals NHS Foundation Trust
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact As Associate Medical Director for Research, I (with my senior leadership team) am developing a new strategy for research for Newcastle Hospitals. This will embed research into everyday care, and provide opportunities for research participation for all levels of hospital staff, linked to training programmes. It is well recognised that research leads to improved healthcare outcomes, and this new strategy should therefore improve the health of our local and regional population, as well as improve th training and knowledge of our staff.
 
Description DRFZ SAB
Geographic Reach Europe 
Policy Influence Type Participation in a advisory committee
URL https://www.drfz.de/en/
 
Description EULAR 2020 Pivotal Events
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact As Scientific Chair of EULAR 2020, I chaired the committee responsible for developing an education and scientific programme of high quality and value. More than 15000 delegates attended this virtual event, which received more than 2 million website 'hits' during the four days of the congress.
URL https://congress2020.eular.org/scientific_programme.cfm
 
Description EULAR Consensus Meeting, Vienna, 2019
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
Impact This committee generated guidance for the use of a new class of drugs in patients with rheumatic diseases.
 
Description EULAR Scientific Committee
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact EULAR'S scientific committee is responsible for developing an education and scientific programme of high quality and value. More than 15000 delegates attend the annual meeting, which is recognised as one of the top two rheumatology congresses annually. I was chair of this committee in 2020 and, as past chair in 2021, continue to play an active role in the activities of the committee.
URL https://congress.eular.org/
 
Description MRC Precision Medicine Group
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://mrc.ukri.org/research/initiatives/precision-medicine/
 
Description MRC Translational Research Group
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://mrc.ukri.org/
 
Description MRC Translational Research Group London 2018
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
URL https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group...
 
Description MRC Translational Research Group, London
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description MRC Translational Research Group, London, 2019
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group...
 
Description Member, UKRI/ DHSC Oversight Committee for Covid-19 Immunology in the UK
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/8958...
 
Description NIHR BRC Impact Showcase, Newcastle, 2018
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Influential meeting on Healthy Ageing as a research priority of national importance, as exemplified by our NIHR BRC.
URL https://www.newcastlebrc.nihr.ac.uk/nihr-newcastle-biomedical-research-centre-impact-showcase-presen...
 
Description Newcastle Health Innovation Partners - Chair of the Research, Innovation & Enterprise Strategy Executive
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in a advisory committee
Impact Newcastle Health Innovation Partners is Newcastle's Academic Health Science Centre, a partnership between Newcastle University, Newcastle upon Tyne hospitals, Cumbria, Northumberland, Tyne and Weir NHS Mental Health Trust, the Academic Health Science Network NE North Cumbria and Newcastle City Council. The aim of the research and innovation strategy group is to develop partnerships that accelerate the adoption of healthcare innovations that have developed from altranslation research activity either within the partner organisations themselves or in partnership with external collaborators. The ultimate aim is to improve the health, wealth and wellbeing of our regional population. We are already making advances in areas such as healthy ageing, rare diseases, advanced therapies and diagnostics. The COVID hub NE is a good example of a partnership that has the potential to improve the health of the local population by the rapid diagnosis and appropriate management of COVID-19 infection.
URL https://www.newcastlehealthinnovation.org/
 
Description Novel Therapies in Rheumatoid Arthritis
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description TRC Steering Committee, London, 2018 with VA and NOCRI
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Versus Arthritis Fellowship Expert Group
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact The Versus Arthritis Fellowships Group, in addition to overseeing the award of a variety of Fellowship types to outstanding candidates, also has an influence on the Charity's Strategy with regard to education and training. An example is to ensure that Fellows receive sufficient resource to perform the research that they are planning. We also review the portfolio of fellowships on offer and decide, with the Charity's senior leadership, whether this remains current and appropriate. The terms of reference are as follows: i. to help monitor the provision of UK musculoskeletal training and identify gaps in support, where additional career support activities could add value ii. to take the role of chair or vice chair of Fellowship Funding Panels from time to time, overseeing the award of individual fellowships and studentships iii. to advise the charity on the balance of career support activities across the three Subcommittees iv. to help devise strategies to attract the brightest and most enthusiastic scientists, clinicians, nurses and allied health professionals into musculoskeletal research v. to advise on strategies to support individuals at different stages of their careers, using knowledge of career paths for all relevant areas vi. to help Versus Arthritis engage and work with others to increase musculoskeletal research capacity in the UK through the identification of potential funding and/or strategic partnerships vii. to contribute to discussion papers and reports on career support for consideration by the Subcommittees, Charitable Purposes Committee and charity Executive viii. to take learnings from the three Subcommittees as well as their expert area in order to make recommendations to the charity ix. to support the annual fellows meeting and propose other career events as appropriate.
URL https://www.versusarthritis.org/media/19590/feg-terms-of-reference.pdf
 
Description Versus Arthritis Fellowship Expert Group
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact Discussion around support for Fellows at various stages of their careers
URL https://www.versusarthritis.org/
 
Description Versus arthritis subcomittee meeting
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://www.versusarthritis.org/
 
Description Wellcome Trust 4WARD Meeting 2016 - Clinical PhD Funding - Newcastle, Leeds, Manchester, Sheffield
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Consortium Clinical PhD Funding Meeting
URL http://www.4wardnorth.org.uk/
 
Description Wellcome Trust Clinical Interview Committee
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact I was an ad hoc member of the Wellcome Trust selection committee for intermediate clinical fellowships on two occasions in 2020. These highly competitive fellowships are awarded to outstanding individuals based in a supportive environment to work on cutting edge scientific projects, ultimately improving the education and skill level of the workforce - these particular fellowships are required to incorporate a training element.
URL https://wellcome.org/grant-funding/guidance/funding-application-advisory-committees/clinical-intervi...
 
Description NIHR Newcastle Biomedical Research Centre in Ageing and Long-term conditions
Amount £17,460,811 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description NIHR Senior Investigator Award
Amount £360,000 (GBP)
Funding ID NIHR200224 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2019 
End 03/2023
 
Description Research into Inflammatory Arthritis Centre Versus Arthritis
Amount £1,999,997 (GBP)
Funding ID 22072 
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 03/2024
 
Description A: RA Centre of Excellence - Birmingham Scientific Meeting. 
Organisation University of Birmingham
Department Birmingham Clinical Trials Unit
Country United Kingdom 
Sector Academic/University 
PI Contribution Workshop on fibroblasts by Lilian Nwosu. Presentations my myself on TRAFIC and BioFlare studies.
Collaborator Contribution Equal partners with Glasgow and Birmingham.
Impact See additional awards and publications stemming from the RACE centre.
Start Year 2015
 
Description A: RA Centre of Excellence - Birmingham Scientific Meeting. 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Workshop on fibroblasts by Lilian Nwosu. Presentations my myself on TRAFIC and BioFlare studies.
Collaborator Contribution Equal partners with Glasgow and Birmingham.
Impact See additional awards and publications stemming from the RACE centre.
Start Year 2015
 
Description ARUK Centre of Excellence in rheumatoid arthritis pathogenesis 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years
Collaborator Contribution Each centre will provide a unique scientific contribution to the Centre
Impact Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University
Start Year 2013
 
Description ARUK Centre of Excellence in rheumatoid arthritis pathogenesis 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years
Collaborator Contribution Each centre will provide a unique scientific contribution to the Centre
Impact Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University
Start Year 2013
 
Description ARUK-NIHR Newcastle Experimental Arthritis Treatment Centre 2016 
Organisation Versus Arthritis
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Clinical, imaging, statistical and bioinformatics support.
Collaborator Contribution Infrastructure support including laboratory technical support, research nurses, project management, biostatistical and database management support. This has been crucial in tendering for other awards and trials.
Impact See Publications
Start Year 2012
 
Description Cyclacel/TRAFIC 
Organisation Cyclacel Ltd
Country United Kingdom 
Sector Private 
PI Contribution We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients
Collaborator Contribution Cyclacel are providing drug and also support in kind for the research. Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements
Impact MRC DPFS/DCS grant for £1.1m
Start Year 2013
 
Description Cyclacel/TRAFIC 
Organisation University of Birmingham
Department Rheumatology Research Group
Country United Kingdom 
Sector Academic/University 
PI Contribution We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients
Collaborator Contribution Cyclacel are providing drug and also support in kind for the research. Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements
Impact MRC DPFS/DCS grant for £1.1m
Start Year 2013
 
Description Cyclacel/TRAFIC 
Organisation University of Glasgow
Department Department of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution We have written a successful MRC MICA grant to repurpose an anti-proliferative drug in rheumatoid arthritis patients
Collaborator Contribution Cyclacel are providing drug and also support in kind for the research. Glasgow and Birmingham are collaborating with us on the research - recruiting patients, performing biomarker measurements
Impact MRC DPFS/DCS grant for £1.1m
Start Year 2013
 
Description RACE 2 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute to joint scientific efforts, as well as leading experimental medicine studies such as TRAFIC, BIO-FLARE and AuToDeCRA 2.
Collaborator Contribution Multiple collaborative scientific studies and grants.
Impact TBD
Start Year 2019
 
Description RACE 2 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution We are partners in this Centre of Excellence
Collaborator Contribution There are four distinct universities comprising the RACE consortium. AuToDeCRA 2 sits within RACE
Impact None yet
Start Year 2019
 
Description RACE 2 
Organisation University of Glasgow
Department School of Medicine Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution We are partners in this Centre of Excellence
Collaborator Contribution There are four distinct universities comprising the RACE consortium. AuToDeCRA 2 sits within RACE
Impact None yet
Start Year 2019
 
Description RACE 2 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute to joint scientific efforts, as well as leading experimental medicine studies such as TRAFIC, BIO-FLARE and AuToDeCRA 2.
Collaborator Contribution Multiple collaborative scientific studies and grants.
Impact TBD
Start Year 2019
 
Description RACE 2 
Organisation University of Oxford
Department Kennedy Institute of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution We are partners in this Centre of Excellence
Collaborator Contribution There are four distinct universities comprising the RACE consortium. AuToDeCRA 2 sits within RACE
Impact None yet
Start Year 2019
 
Description RACE 2 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Contribute to joint scientific efforts, as well as leading experimental medicine studies such as TRAFIC, BIO-FLARE and AuToDeCRA 2.
Collaborator Contribution Multiple collaborative scientific studies and grants.
Impact TBD
Start Year 2019
 
Description RACE Scientific Meeting, Newcastle, 2018 
Organisation University of Birmingham
Department Birmingham University Imaging Centre (BUIC)
Country United Kingdom 
Sector Academic/University 
PI Contribution Hosted by Newcastle. Showcase collaborative opportunities with presentations by Andy Mellor, Shoba Amarnath, Andy Filby together with clinical research updates.
Collaborator Contribution All contributed actively and gave valuable feedback.
Impact Scientific strategic planning outputs and plans for further collaboration.
Start Year 2015
 
Description RACE Scientific Meeting, Newcastle, 2018 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Hosted by Newcastle. Showcase collaborative opportunities with presentations by Andy Mellor, Shoba Amarnath, Andy Filby together with clinical research updates.
Collaborator Contribution All contributed actively and gave valuable feedback.
Impact Scientific strategic planning outputs and plans for further collaboration.
Start Year 2015
 
Description RACE Scientific Meeting, Newcastle, 2018 
Organisation University of Oxford
Department Kennedy Institute of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution Hosted by Newcastle. Showcase collaborative opportunities with presentations by Andy Mellor, Shoba Amarnath, Andy Filby together with clinical research updates.
Collaborator Contribution All contributed actively and gave valuable feedback.
Impact Scientific strategic planning outputs and plans for further collaboration.
Start Year 2015
 
Description RACE-2 Scientific Meeting, Glasgow 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution RACE is a four-partner academic consortium focussed on inflammatory arthritis pathogenesis. Our annual reports demonstrate multiple linked outputs in terms of publications, successful PhD studentships, industrial interactions and congress presentations.
Collaborator Contribution See above
Impact TBD
Start Year 2020
 
Description RACE-2 Scientific Meeting, Glasgow 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution RACE is a four-partner academic consortium focussed on inflammatory arthritis pathogenesis. Our annual reports demonstrate multiple linked outputs in terms of publications, successful PhD studentships, industrial interactions and congress presentations.
Collaborator Contribution See above
Impact TBD
Start Year 2020
 
Description RACE-2 Scientific Meeting, Glasgow 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution RACE is a four-partner academic consortium focussed on inflammatory arthritis pathogenesis. Our annual reports demonstrate multiple linked outputs in terms of publications, successful PhD studentships, industrial interactions and congress presentations.
Collaborator Contribution See above
Impact TBD
Start Year 2020
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation National Institute for Health Research
Country United Kingdom 
Sector Public 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Cambridge
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation University of Southampton
Country United Kingdom 
Sector Academic/University 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Description Translational Research Collaboration for rheumatic and inflammatory diseases 
Organisation Versus Arthritis
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Strategic Planning of experimental medicine studies.
Collaborator Contribution Strategic Planning of experimental medicine studies.
Impact A number of clinical trials have been completed and published
Start Year 2013
 
Title TRAFIC:Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition 
Description Targeting the RA synovial fibroblast via cyclin dependent kinase inhibition ? - an early phase trial (TRAFIC): a non-randomised trial. Site set-up at three centres in the UK. Outsourcing of PK to Charles River and clinical trial packaging activities to third party. Part 1 (Identification of maximium tolerated dose by Continuous reassessment modelling completed October 2017. 
Type Therapeutic Intervention - Drug
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2017
Development Status Under active development/distribution
Clinical Trial? Yes
Impact Recruitment of two additional sites. First use of continuous reassessment modelling algorithm dose escalation study outside of oncology. 
URL http://www.isrctn.com/ISRCTN36667085?
 
Title COLLABORATOR In-House Software 
Description Software tool permitting continuous reassessment modelling algorithm to determine dose escalation allowing recruitment of patients to a complex trial across multiple collaborator sites. 
Type Of Technology Webtool/Application 
Year Produced 2017 
Impact May be of commercial interest. 
 
Description "Bones" Exhibition at the Great North Museum 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Workshops, demonstrations, talk, events and public information materials presented in parallel with the Bones Exhibition at the Great North Museum highlighting musculoskeletal research at our Centres of Excellence at Newcastle University including the Centre for Integrated Musculoskeletal Ageing, the Newcastle Experimental Arthritis Treatment Centre, the Rheumatoid Arthritis Centre of Excellence and the Newcastle Biomedical Research Centre.
Year(s) Of Engagement Activity 2017
URL https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world
 
Description 4th International Workshop on Therapeutic Tolerancing 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Every 4 years Newcastle University hosts its international workshop on Clinical Therapeutic Tolerance. Previous editions covered 'Therapeutic Tolerance: Myth or Reality?' (2005), 'Therapeutic Tolerance: Closer to Reality?' (2009) and 'Therapeutic Tolerance: Tolerance Inducing Strategies in the Clinic'. (2013)

Our fourth workshop carried the title 'Therapeutic Tolerance: First-in-Human Data' and was held from 27th - 30th June 2017. Main focus of the meeting was the analysis of data from the first therapeutic tolerance trials.

The popular programme allows ample time for discussion and true debate, with an opportunity for poster presentations (with prizes). This international workshop is attended by leading scientists and practitioners in the field from around the world.
Year(s) Of Engagement Activity 2017
URL https://www.newcastlebrc.nihr.ac.uk/news/therapeutic-tolerance-first-human-data-event/
 
Description 9th International Symposium on Uveitis Dublin 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lecture on Biologics in Rheumatology
Year(s) Of Engagement Activity 2016
 
Description ADARRC - RA Summit - Abu Dhabi 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The 7th annual Abu Dhabi Advanced Rheumatology Review Course provided a comprehensive update on adult and paediatric rheumatology. Designed as a three-day, intensive rheumatology course, ADARRC is a series of lectures and workshops delivered by global experts to provide new insights, case studies and pioneering research findings.
Year(s) Of Engagement Activity 2017
URL http://adarrc.org/
 
Description ARUK Arthritis Matters 2014 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact There was useful discussion after my presentation about the reach of charitable funding

Patients volunteered to join TRAFIC steering group
Year(s) Of Engagement Activity 2014
URL http://www.musculoskeletalresearch.com/2014/07/arthritis-matters-2014.html
 
Description ARUK RACE Annual Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. We meet face to face three times per year.
Year(s) Of Engagement Activity 2017
URL http://www.race-gbn.org/
 
Description ARUK RACE Meeting - Glasgow 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers.
Year(s) Of Engagement Activity 2017
URL http://www.race-gbn.org/
 
Description ARUK RACE Scientific Meeting - Birmingham 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers.
Year(s) Of Engagement Activity 2017
URL http://www.race-gbn.org/
 
Description ARUK RACE Scientific Meeting - Newcastle 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers.
Year(s) Of Engagement Activity 2017
URL http://www.race-gbn.org/
 
Description ARUK strategy meeting - Chesterfield 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact A meeting to update us on the charity (Arthritis Research UK), and particularly its recent merger with Arthritis Care. Also a useful discussion around future research directions.
Year(s) Of Engagement Activity 2017
URL http://www.arthritisresearchuk.org/
 
Description Amsterdam seminar and potential collaboration 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Seminar - New concepts and novel targets in RA management, including DC therapy. Also met one-to-one with several potential collaborators; I anticipate this will lead to a collaboration around immune monitoring in AuToDeCRA 2.
Year(s) Of Engagement Activity 2019
URL https://ams-rc.com/en/
 
Description BSR Manipulating The Immune System - Birmingham 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact This was a lecture to rheumatologists in training on novel immunologically based therapies, at the annual BSR AGM.
Year(s) Of Engagement Activity 2017
URL https://www.eiseverywhere.com/ehome/rheumatology2017/423982/
 
Description Bones Exhibition Great North Museum 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Design input to Learning Zone activities supporting the Exhibition. Posters and public information leaflets.
Year(s) Of Engagement Activity 2017
URL https://greatnorthmuseum.org.uk/whats-on/bones-skeleton-secrets-of-the-animal-world
 
Description Central & Eastern European Immunology Forum Bucharest 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact New Treatments for Immune Mediated Inflammatory Diseases
Year(s) Of Engagement Activity 2016
 
Description Dutch Rheumatology Days 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Utrecht Rheumatology Workshop
Year(s) Of Engagement Activity 2016
 
Description EMINENT Science Day and Scientific Co-ordinating Committee, Stevenage 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact EMINENT (Experimental Medicine Initiative to Explore New Therapies) is a consortium funded by GSK and MRC, with some contribution (eg towards fellowships) from NIHR. EMINENT brings together investigators from University College London (UCL), the University of Cambridge, the University of Glasgow, the University of Newcastle, Imperial College London and GlaxoSmithKline (GSK), with unprecedented access to GSK's unlicenced clinic-ready asset portfolio to enable experimental medicine studies aimed at enhancing understanding of disease mechanisms and accelerating development of novel therapeutics for patients in under-served disease areas. At this meeting our work on OSM< funded by EMINENT, was presented and discussed.
Year(s) Of Engagement Activity 2020
URL https://www.ucl.ac.uk/eminent-consortium/
 
Description EULAR 2019 Organizing Committee 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Preparing for EULAR 2019 (Madrid). JDI is Abstracts Chair, a majpr role in the organising committee..
Year(s) Of Engagement Activity 2018,2019
URL https://www.congress.eular.org
 
Description EULAR AGM planning meeting, Zurich 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This is the committee that plans the annual scientific meeting for the European League Against Rheumatism.
Year(s) Of Engagement Activity 2017
URL http://www.eular.org
 
Description EULAR Scientific Committee - Amsterdam 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This is the committee that plans the annual scientific meeting for the European League Against Rheumatism. I am the chair of this committee from 2018-2020.
Year(s) Of Engagement Activity 2018
URL http://www.congress.eular.org/?utm_source=google&utm_medium=cpc&utm_campaign=registration&gclid=CjwK...
 
Description EULAR Scientific Programme Committee 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Planning meeting for EULAR 2019 in Madrid. As Abstract Chair I play a major role in this meeting.
Year(s) Of Engagement Activity 2018
URL http://congress.eular.org/index.cfm
 
Description Faculty visit to Dublin 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact THis was an information exchange between FMS at Newcastle and the equivalent at Trinity, Dublin. I presented our immunology portfolio and they did the same. Others talked about ageing and neuroscience research Successful meeting.
Year(s) Of Engagement Activity 2019
 
Description GSK Industry Engagement Visit Newcastle 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Explored shared interests - potential for interaction - biopsy procedures
Year(s) Of Engagement Activity 2016
 
Description Great North Experimental Arthritis Treatment Centre website 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact The activity is ongoing
Year(s) Of Engagement Activity 2014
URL http://www.greatneatcentre.com/
 
Description International Forum for RA 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The International Forum for RA is a meeting focussed on cutting edge research in rheumatoid arthritis, with an emphasis on influencing future management strategies. I gave a presentation around 'smart trial designs'. This led to a new collaboration with Dana Orange (Rockefeller).
Year(s) Of Engagement Activity 2017
 
Description J-TRC Meeting Q3 - London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The NIHR Translational Research Collaboration for Joint and Related Inflammatory Diseases aims to assist industrial partners is early phase experimental medicine studies, by providing a national network of academic centres skilled in this type of research. Each meeting discusses opportunities, ongoing studies and general strategy.
Year(s) Of Engagement Activity 2017
URL https://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-...
 
Description JTRP Steering Committee Meeting - London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The NIHR Translational Research Collaboration for Joint and Related Inflammatory Diseases aims to assist industrial partners is early phase experimental medicine studies, by providing a national network of academic centres skilled in this type of research. Each meeting discusses opportunities, ongoing studies and general strategy.
Year(s) Of Engagement Activity 2017
URL https://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-...
 
Description Joint Effort Support Group, Alnwick 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact I gave a presentation entitled Modern Management of Rheumatoid Arthritis - a Cure is in Sight, to a regional National Rheumatoid Arthritis Society group
Well received, lots of questions
Year(s) Of Engagement Activity 2019
URL https://www.nras.org.uk/groups/joint-effort-group-alnwick
 
Description MRC DPFS Meeting - London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including "repurposing" of existing therapies.
Remit
The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.
Year(s) Of Engagement Activity 2018
URL https://www.mrc.ac.uk/funding/browse/biomedical-catalyst-dpfs/biomedical-catalyst-developmental-path...
 
Description MRC Industrial Challenge Strategy Workshop 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact This was a strategic planning meeting that informed the 2017/18 topics for the Industrial Strategy Challenge Fund call.
Year(s) Of Engagement Activity 2017
 
Description MRC Research Strategy Visit 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Reviewed medical research at Newcastle highlighting achievements in experimental medicine and translational research and identifying improvement opportunities.
Year(s) Of Engagement Activity 2016
 
Description MRC TRG Meeting - London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The MRC Translational Research Group (TRG) is responsible for ensuring strong continued support for translational research across the MRC. It supports translational research across MRC funding Boards and Panels, through partnerships with other funders and major Higher Education Institutions and through dedicated funding schemes. Areas of particular focus for TRG include:
The Biomedical Catalyst, an integrated translational funding programme jointly operated with Innovate UK (formerly the Technology Strategy Board).
The Confidence in Concept scheme, supporting academically led feasibility research at the institutional level.
The Developmental Pathway Funding Scheme, part of the Biomedical Catalyst, supporting translation of fundamental discoveries toward benefits to human health.
The Methodology Research Programme, in partnership with the National Institute for Health Research (NIHR).
Coordination with the MRC-NIHR Efficacy and Mechanism Evaluation Programme (EME) programme and other NIHR funding schemes to ensure suitable projects progress to late-stage trials.
Year(s) Of Engagement Activity 2017
URL https://www.mrc.ac.uk/about/our-structure/strategy-board-overview-groups/translational-research-grou...
 
Description NE Regional Meeting - Newcastle 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Regional Newcastle Meeting of Rheumatology Professionals, focussed on early rheumatoid arthritis and at risk individuals. I presented on tolerance-inducing strategies
Year(s) Of Engagement Activity 2017,2018
 
Description NIHR BRC Impact Showcase, Newcastle, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Showcase event attended by senior figures from the Department of Health and major charities including Versus Arthritis. The CEOs of the Trust and University attended. Musculoskeletal presentations included patient presentations and videos. Ken Baker was awarded a prize for best oral presentation. Sir John Burn and Dame Jackie Daniel presented their vision for Newcastle.
Year(s) Of Engagement Activity 2018
URL https://www.newcastlebrc.nihr.ac.uk/events/nihr-newcastle-biomedical-research-centre-impact-showcase...
 
Description NIHR Biomedical Research Centre Directors Meeting - London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Discussions around expectations for the newly funded NIHR BRCs..
Year(s) Of Engagement Activity 2017
URL https://www.nihr.ac.uk/about-us/how-we-are-managed/our-structure/infrastructure/biomedical-research-...
 
Description Newcastle Upon Tyne Hospitals - Rheumatoid Arthritis Where Next? 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Presentation on future RA research directions to junior doctors and medical staff in the NUTH Trust
Year(s) Of Engagement Activity 2016
 
Description OK To Ask 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? Yes
Geographic Reach Regional
Primary Audience Participants in your research and patient groups
Results and Impact Talks and poster sessions promoting participation in Newcastle Experimental Arthritis Treatment Centre.

Generated questions, discussion and approaches from members of the public interested in participating in arthritis research.

Patients contacted Research Nurses enquiring about participation in research.
Year(s) Of Engagement Activity 2015
URL http://www.nihr.ac.uk/oktoask
 
Description Pfizer visit to Newcastle 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A sizeable delegation of senior Pfizer personnel - scientific and business - visited for the day. They heard about our research, our electronic patient record, and the joint relationship between NHS and University - amongst other things. Pans were made for further interactions - which are now planned for Q2 2020.
Year(s) Of Engagement Activity 2019
 
Description Plenary lecture and dinner at House of Commons - Ten Topics 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lecture - New Therapies, Future Cures. As part of this meeting i attended a speakers dinner at the House of Commons and spoke with a number of MPs about arthritis and our work. In particular I chatted over dinner with Estelle Morris, sec state for education 2001-02.
Year(s) Of Engagement Activity 2019
URL http://www.tentopics.com/uploads/Topics-Programme-2019.pdf
 
Description Portuguese Society of Rheumatology - Algarve 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote Lecture - New Treatments for IMID - invited paper to Annals Review
Year(s) Of Engagement Activity 2016
 
Description RA Regional Meeting - Middlesbrough 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Sharing best practice around updates on the management of rheumatoid arthritis.
Year(s) Of Engagement Activity 2017
 
Description RA Regional Meeting - Newcastle 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Sharing best practice and providing an update on novel approaches to RA management.
Year(s) Of Engagement Activity 2017
 
Description RACE Annual Review 2016 Birmingham 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Annual review chaired by Ann Cooke. Caroline Aylott and Craig Bullock. Re-aligned research focus for 2016-2017.
Year(s) Of Engagement Activity 2016
 
Description RACE Meeting Newcastle 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Planning for the ARUK 'cure' call.
Year(s) Of Engagement Activity 2016
 
Description RACE Scientific Advisory Board Meeting 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentations on TRAFIC and BIO-FLARE as worked examples of our experimental medicine approach.
Year(s) Of Engagement Activity 2016
 
Description RACE Scientific Meeting - Glasgow 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA Centre of Excellence in RA pathogenesis is an infrastructure award from Arthritis Research UK that supports a collaboration between Newcastle, Birmingham and Glasgow. We write grants together, support a cadre of PhD students and engage with patients and carers. This was the annual scientific meeting.
Year(s) Of Engagement Activity 2017
URL http://www.race-gbn.org/
 
Description RACE Scientific Meeting, Birmingham, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Scientific updates including progress with TRAFIC and BioFLARE.
Year(s) Of Engagement Activity 2018
 
Description RACE Scientific Meetings 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Active participation in RACE Scientific Meetings bringing together arthritis researchers and patient partners. There are three or four meetings per year , attended by collaborators, students and patient partners. The patient partners form an important constituency and a major effort is made to ensure that presentations are suitable for such an audience
Year(s) Of Engagement Activity 2019,2020,2021
URL https://www.race-gbn.org/news/
 
Description RACE Second International Scientific Advisory Board Meeting, Glasgow, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact Scientific presentations and patient-focused discussions. Excellent feedback from the panel, which has influenced.renewal plans.
Year(s) Of Engagement Activity 2018
URL http://www.race-gbn.org/communityengagement/
 
Description RACE launch 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Interesting discussions, including with an Olympian

None yet
Year(s) Of Engagement Activity 2014
 
Description Refractory Rheumatoid Arthritis - York 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Keynote lecture on Refractory RA at the Northern group annual meeting
Year(s) Of Engagement Activity 2016
 
Description Research Engagement Poster Campaign 2015 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Poster campaign describing research in lay terms for public and patients audience. To promote engagement in research in the NE.

Public and patients expressed interest in participating in research.
Year(s) Of Engagement Activity 2015
 
Description Rheumatoid Arthritis Strategic Review, Newcastle, 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Strategic realignment of research activities
Year(s) Of Engagement Activity 2015
 
Description Rounds at Queen Mary Hospital, Hong Kong 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact During my trip to Hong Kong for the ICCR I visited Queen Mary Hospital where I discussed some complex cases and gave a seminar: Prevention of RA - pipedream or possibility?
Year(s) Of Engagement Activity 2019
URL https://www8.ha.org.hk/qmh/
 
Description South African Immunology Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact University of Pretoria Basic Immunology and Immunology in RA.
Year(s) Of Engagement Activity 2016
 
Description TEDx Newcastle 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact It provided an opportunity to highlight the importance of patient participation in experimental medicine and translational research studies

The TEDx Newcastle website has received more than 10000 hits
Year(s) Of Engagement Activity 2014
URL http://www.greatneatcentre.com/2014/07/the-patient-who-changed-my-life-people.html
 
Description Targeted Therapies Meeting - Mallorca 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invite only meeting. Session chair.
Year(s) Of Engagement Activity 2016
 
Description UK Autoimmunity Workshop - Defining the Grand Challenges - Clinical Trials, New Therapeutics, Repurposing 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact JDRF
MRC
ARUK
WT
Year(s) Of Engagement Activity 2016
 
Description Zing Conference Spain 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Prospective collaborations and partnerships
Year(s) Of Engagement Activity 2015
 
Description seminar to rheumatologists St Gallen Switzerland 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited seminar - New concepts and novel targets in RA management to a mix of academic and non-academic Swiss rheumatologists.
Year(s) Of Engagement Activity 2019